TrialBlood2012

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

Hagop M Kantarjian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.